Literature DB >> 708725

A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers.

R Goldman, T Facchinetti, D Bach, A Raz, M Shinitzky.   

Abstract

Drug-membrane association of daunomycin, adriamycin and three of its derivatives, adriamycin-14-octanoate (AD-14-OCTA), adriamycin-14-acetate (AD-14-ACE) and N-trifluoroacetyladriamycin-14-valerate (AD32), was studied using phospholipid bilayers and human erythrocytes. The various drugs exhibited a differential affinity to membrane-lipid domains. Lipid-incorporated drugs exhibit a marked change in the shape of the emission spectrum which was utilized for the evaluation of the apparent dielectric constant, epsilon, of the environment surrounding the anthracycline moiety, as well as for the determination ofthe partitioning constant. By measuring the fluorescence polarization and the fluorescence lifetime of the incorporated drugs, rotational relaxation times of 4--8 ns were derived. These parameters provide a supportive evidence of the association of the fluorophore of the drugs with membrane-lipid domains. The anthracycline derivatives interact to a different degree with dipalmitoyl phosphatidylcholine and phosphatidylserine as reflected by changes in their thermotropic properties assessed by differential scanning calorimetry. Daunomycin was the most effective in decreasing the temperature of the phase transition and brought about a comparable reduction in the enthalpy of melting as AD32 and AD-14-OCTA. Adariamycin was the least potent of the series. AD-14-ACE and AD32 protected erythrocytes against hypotonic lysis, adriamycin and daunomycin had no significant effect on the susceptibility to hypotonic lysis, whereas AD-14-OCTA proved to be hemolytic even at low concentration (approx. 10(-7M).

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708725     DOI: 10.1016/0005-2736(78)90251-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?

Authors:  D J Morré; C Kim; M Paulik; D M Morré; W P Faulk
Journal:  J Bioenerg Biomembr       Date:  1997-06       Impact factor: 2.945

2.  The influence of lipoic acid on adriamycin induced nephrotoxicity in rats.

Authors:  Kumaravel Palanichamy Malarkodi; Andithangal Venkatesan Balachandar; Palaninathan Varalakshmi
Journal:  Mol Cell Biochem       Date:  2003-05       Impact factor: 3.396

3.  Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group.

Authors:  T G Burke; A C Sartorelli; T R Tritton
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Verapamil prevents the effects of daunomycin on the thermotropic phase transition of model lipid bilayers.

Authors:  J M Canaves; J A Ferragut; J M Gonzalez-Ros
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

5.  Differential adriamycin distribution to blood components.

Authors:  T Colombo; M Broggini; S Garattini; M G Donelli
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1981       Impact factor: 2.441

6.  Binding of adriamycin to liposomes as a probe for membrane lateral organization.

Authors:  T Söderlund; A Jutila; P K Kinnunen
Journal:  Biophys J       Date:  1999-02       Impact factor: 4.033

7.  Inhibition of plasma membrane NADH dehydrogenase by adriamycin and related anthracycline antibiotics.

Authors:  I L Sun; F L Crane; H Löw; C Grebing
Journal:  J Bioenerg Biomembr       Date:  1984-06       Impact factor: 2.945

8.  Physical entrapment of adriamycin in AB block copolymer micelles.

Authors:  G S Kwon; M Naito; M Yokoyama; T Okano; Y Sakurai; K Kataoka
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

9.  Acute doxorubicin insult in the mouse ovary is cell- and follicle-type dependent.

Authors:  Elon C Roti Roti; Scott K Leisman; David H Abbott; Sana M Salih
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

10.  Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity.

Authors:  Yan-feng Song; Dao-zhou Liu; Ying Cheng; Miao Liu; Wei-liang Ye; Bang-le Zhang; Xin-you Liu; Si-yuan Zhou
Journal:  Sci Rep       Date:  2015-11-04       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.